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Background: Papillary thyroid carcinoma is rarely associated with metastatic disease. The most common sites of
metastasis are the lungs and bones, while only few cases of ovarian metastasis are described in literature.
Case: We report the case of a 51 years old woman, treated 9 years before for papillary thyroid carcinoma,
presenting to our Institute with a pelvic ovarian mass revealed by ultrasound imaging. After bilateral salpingo-
oophorectomy, the histologic examination detected a left ovarian metastasis from papillary thyroid carcinoma.
Conclusion: Even if the diagnosis of ovarian metastasis from thyroid carcinoma is often controversial, it should be
considered when a woman with an ovarian lesion of unknown origin, has a personal history of malignant thyroid
disease.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_193
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Papillary thyroid carcinoma is the most common histo-
type of thyroid carcinoma and it is associated to a good
prognosis and to a loco regional spread. The presence of
distant metastasis is an important prognostic factor, al-
though it is a rare event. Distant metastasis from papil-
lary thyroid carcinoma often occurs decades after the
primary tumor and the 70% of patients who die for pap-
illary thyroid carcinoma are disease free after the pri-
mary treatment. Moreover, the 30 years mortality rates
increase to 43% as a result of a distant recurrence [1,2].
The most common metastatic sites are lung [3] and,
following, bone. Instead, rare metastatic sites are brain,
parotid, breast, liver, kidney, adrenal glands, ovaries,
muscle and skin [4].
Ovaries are the most common metastatic sites from
both genital and extragenital primaries, mostly originat-
ing in the gastrointestinal tract, and ovarian metastasis
represent about 5% to 30% of all ovarian tumors [5,6].* Correspondence: giacomo.corrado@alice.it
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unless otherwise stated.We report a rare case of ovarian metastasis from thy-
roid carcinoma after 9 years from the diagnosis.Case presentation
In December 2013 a 51 years old woman presented to
our Gynecologic Oncology Unit, for the presence of a
pelvic mass originating from the left ovary, occasionally
detected in the ultrasound imaging during a routine
check. She was 1 gravida, 1 para, with no previous
gynecological pathology in her history. She referred that
in 2004, following diagnosis of thyroid carcinoma, she
underwent a total thyroidectomy in another hospital.
The histological examination revealed a papillary thyroid
carcinoma, follicular variant, involving the left thyroid
lobe. She received a radio-iodine metabolic adjuvant
treatment by administration of 120 mCi 131I.
No evidence of disease was detected during follow up
until December 2013 when an ovarian mass was re-
vealed by ultrasound imaging and at the magnetic reson-
ance it measured 76 × 46 × 62 mm (Figure 1). Normal
value resulted for Ca125 and HE4 (respectively 23.9 UI/ML
and 100 pmol/L), while thyroglobulin was detectable
(0.2 ng/ml). She underwent laparoscopic bilateral salpingo-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pelvic magnetic resonance. A) Axial fat suppressed T1-weighted image after intravenous gadolinium enhancement. B) Sagittal
T2-weighted image showing left solid ovarian mass.
Figure 2 Microscopic examination and immunohistochemical stains. A) The ovarian parenchyma is occupied by a thyroid type neoplasm.
Note the follicles. (HE 40×). B) Massive extension of the neoplasm in the parenchyma. There is no evidence of benign struma ovary or others
components of teratoma (HE 40×). C) Follicular and papillary components of neoplasm (HE 100×). D) Papillary component of neoplasm. Papillae
are lined by cells with ground glass nuclei. There are also some mitoses (HE 400×). E) Positive reaction of thyroglobulin antibody (HE 400×).
F) Nuclear positive reaction of TTF-1 antibody (HE 100×).
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Figure 3 Other immunohistochemical characteristics. A) Positive
reaction for CK-19 (HE 100×). B) Positive reaction for HBME-1 (HE 100×).
C) Negative reaction for GAL-3 (HE 100×).
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thyroid carcinoma involving left ovary. The ovarian tumor
measured 10 × 5 × 6 cm and weighed 700 g. The section
surface was solid and brown. We have performed one sam-
ple per centimeter of maximum dimension. Microscopic
examination showed that ovarian parenchyma was nearly
entirely occupied by thyroid-type neoplasm (Figure 2A-B)
characterized by round follicles, of any size, and papillae
(Figure 2C). Many follicles were lined by cuboidal, epithelial
cells with moderate amounts of cytoplasm and round to
oval and ground glass nuclei that exhibited frequent mitotic
figures (Figure 2D). These cells were also positive to TTF-1
and Thyroglobulin antibodies (Figure 2E-F). Moreover,
Keratin-19 (CK-19) e HBME-1 were positive while
Galectin-3 (GAL-3) was negative (Figure 3A-B-C).
This neoplasm was suggestive for a metastasis because
there was no evidence of benign struma ovary and the
others teratomatous component.
Unfortunately, in March 2014 the CT/PET detected a
left pelvic lymph nodes recurrence (SUV 10.8) and a
paramedian nodular mass in proximity of the uterus
(SUV 10.6). A laparoscopic evaluation showed left pelvic
peritoneal carcinomatosis and a large left pelvic adeno-
pathy (Figure 4). A left pelvic lymphadenectomy and a
left pelvic peritonectomy were performed. Definitive
histological examination showed a metastasis from pap-
illary thyroid carcinoma. Actually, the patient is under-
going biological treatment with multikinase inhibitors.
Conclusions
Papillary thyroid carcinoma is associated with a good
prognosis and with a low metastatic power. A distant
metastasis from papillary thyroid carcinoma is a rare
event, above all when the recurrence occurs in less com-
mon sites. For this reason, rare metastasis is often not
considered during the clinical setting.
When an ovarian mass is found to contain cells with
features of thyroid carcinoma, a differential diagnoses
should have to be considered between thyroid cancer
arising from a struma ovarii and ovarian metastasis ori-
ginating from a primary thyroid carcinoma, since the
prognosis and clinical management are different. Thy-
roid carcinoma originating from a struma ovarii, pre-
senting a papillary histotype in 70% of all cases, is
reported to occur much more commonly than an ovar-
ian metastasis from the thyroid. As a matter of fact,
struma ovarii are the 5% of ovarian teratomas, 5–10%
results in malignant teratomas and metastatic diseases
doesn’t reach the 23% of cases. However, when no tera-
tomatous elements and no normal thyroid epithelial tis-
sue are detected in the ovarian lesion, the diagnosis of
metastasis with a thyroid origin is suggestive [7]. In our
patient, the ovarian parenchyma was completely occu-
pied by thyroid-type neoplasm, there was no evidence ofbenign struma ovary or others teratomatous component
and cells were positive to TTF-1 and Thyroglobulin
antibodies.
A review of literature from 1929 to 2013 can confirm
the rarity of the ovarian metastasis from thyroid carcin-
oma. As it is shown in Table 1, only four case reports of
ovarian metastasis from thyroid are described in a com-
prehensive manner [8-11]. The table shows that most of
Figure 4 Laparoscopic and CT/PET characterization of the pelvic recurrence. A) Laparoscopic image of left pelvic peritoneal carcinomatosis.
B) The large left pelvic lymphadenopathy. C) CT/PET image of a nodular mass near the uterus (SUV 10.6). D) Left pelvic lymph nodes (SUV 10.8).
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fourth and fifth decades of life at the moment of the first
diagnosis and underwent I131 therapy after primary sur-
gery. Moreover, ovarian metastasis seems to appear
more commonly unilaterally. It can be inferred from the
description of these cases that well differentiated thyroid
carcinomas can give metastasis many years after the
primary tumor. As a matter of fact, in Brogioni S et al.
[10] case report, the ovarian metastasis occurred almost
5 years after the first pulmonary metastasis and 7 years
after the first diagnosis. Also in Pirvu A et al. [11]
report, the pulmonary metastasis occurred shortly after
the thyroidectomy, while ovarian metastasis 11 years
after the first diagnosis of thyroid carcinoma. Further-
more, in the well differentiated thyroid cancer group,
papillary histotype seems to give ovarian metastasis
more frequently than follicular. In our case ovaries hadTable 1 Literature review of ovarian metastasis from thyroid




1994 1 17 Partial thyroidectomy Follicular -
Logani S
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2014 1 42 Total tyroidectomy Papillary Yes
NED = no evidence of disease. DOD = death of disease. AWD = alive with disease.been the first metastatic site, while in three of the men-
tioned reports [8,10,11], the ovarian metastasis was asso-
ciated with a metastatic spread, probably pointing to a
biologically more aggressive disease and to a worse prog-
nosis associated to the ovarian involvement. Further 10
cases [12-18] of ovarian spread from thyroid carcinoma
are mentioned in literature but, unfortunately, no more
details were provided. Besic et al. [12] in his autoptic series
reported one case of ovarian metastasis from anaplastic
thyroid carcinoma, while Silvesberg et al. [13], always in
autoptic series, reported two cases of ovarian metastasis
from anaplastic thyroid carcinoma and one from medul-
lary thyroid carcinoma. Others two cases of ovarian
metastasis from medullary thyroid carcinoma are only
mentioned by Ibanez et al. [14] and Gordon et al. [15]. In
another article [17] the ovarian involvement was bilateral.











144 Brain, ovaries Right cystectomy - DOD, 150






- Lungs, ovaries Left ovariectomy Yes AWD, 158
108 Ovaries Laparoscopic bilateral
oophorectomy
No AWD, 111
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management of ovarian metastasis from thyroid cancer.
131I scan and serum thyroglobulin are widely employed
during the follow up of thyroid cancer and in the assess-
ment of the best therapy to use after surgery, while immu-
nohistochemical stain for thyroglobulin and TTF-1 is
often essential in pathologic diagnosis as it has been in
our experience. Moreover, Keratin-19 (CK-19) e HBME-1
were positive while Galectin-3 (GAL-3) was negative. This
was due to because GAL-3 is a useful marker for diagnosis
of low grade thyroid carcinomas [19] while in our case the
carcinoma was an high grade.
In conclusion, the ovarian involvement by a primary
thyroid cancer is a rare event, but it should be consid-
ered, since it seems to be a negative prognostic factor
worsening the oncological outcome. The histopathologic
evaluation, including immunohistochemical stain and
the investigation of patient’s history are crucial steps in
the diagnosis and clinical management of ovarian metas-
tasis from thyroid cancer.
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